PACIRA BIOSCIENCES, INC. Deferred Income Tax Expense (Benefit)
PACIRA BIOSCIENCES, INC. (PCRX) reported Deferred Income Tax Expense (Benefit) of $6.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$3.74M, a 206.73% decline year-over-year.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $8.07M, a 623.95% increase year-over-year.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $752.00K, a 94.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was $1.40M, a 59.66% decline year-over-year.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for fiscal 2025 was $6.48M, a 68.59% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for fiscal 2024 was $20.62M, a 32.06% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for fiscal 2023 was $15.62M.
- PACIRA BIOSCIENCES, INC. deferred income tax expense (benefit) for fiscal 2022 was -$7.95M, a 173.08% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.33M derived: sum of 2 quarters · filed 2026-02-26 | $5.08M derived: sum of 3 quarters · filed 2026-02-26 | $6.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.82M derived: sum of 2 quarters · filed 2025-11-06 | $10.22M 10-Q · filed 2025-11-06 | $13.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $752.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.15M 10-Q · filed 2025-08-05 | $5.66M derived: sum of 3 quarters · filed 2026-02-26 | $6.77M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $1.40M 10-Q · filed 2025-05-08 | $4.91M derived: sum of 2 quarters · filed 2026-02-26 | $6.02M derived: sum of 3 quarters · filed 2026-02-26 | $18.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.62M derived: sum of 2 quarters · filed 2026-02-26 | $17.16M derived: sum of 3 quarters · filed 2026-02-26 | $20.62M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.65M derived: sum of 2 quarters · filed 2025-11-06 | $17.11M 10-Q · filed 2025-11-06 | $23.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $12.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $16.00M 10-Q · filed 2025-08-05 | $22.60M derived: sum of 3 quarters · filed 2026-02-26 | $27.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.46M 10-Q · filed 2025-05-08 | $10.06M derived: sum of 2 quarters · filed 2026-02-26 | $14.98M derived: sum of 3 quarters · filed 2026-02-26 | $26.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.52M derived: sum of 2 quarters · filed 2026-02-26 | $22.96M derived: sum of 3 quarters · filed 2026-02-26 | $15.62M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $16.36M derived: sum of 2 quarters · filed 2024-11-06 | $9.01M 10-Q · filed 2024-11-06 | -$1.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $4.10M 10-Q · filed 2024-07-30 | -$6.74M derived: sum of 3 quarters · filed 2025-02-27 | -$6.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$7.34M 10-Q · filed 2024-05-07 | -$18.18M derived: sum of 2 quarters · filed 2025-02-27 | -$17.48M derived: sum of 3 quarters · filed 2025-02-27 | -$15.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$10.14M derived: sum of 2 quarters · filed 2025-02-27 | -$7.97M derived: sum of 3 quarters · filed 2025-02-27 | -$7.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | $702.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.87M derived: sum of 2 quarters · filed 2023-11-02 | $2.90M 10-Q · filed 2023-11-02 | $814.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $2.19M 10-Q · filed 2023-08-02 | $112.00K derived: sum of 3 quarters · filed 2024-02-29 | $5.45M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $29.00K 10-Q · filed 2023-05-03 | -$2.05M derived: sum of 2 quarters · filed 2024-02-29 | $3.29M derived: sum of 3 quarters · filed 2024-02-29 | $9.15M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.26M derived: sum of 2 quarters · filed 2024-02-29 | $9.13M derived: sum of 3 quarters · filed 2024-02-29 | $10.87M 10-K · filed 2024-02-29 |
| 2021-09-30 | $5.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $11.21M derived: sum of 2 quarters · filed 2022-11-03 | $12.95M 10-Q · filed 2022-11-03 | $10.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $7.61M 10-Q · filed 2022-08-03 | $5.57M derived: sum of 3 quarters · filed 2023-02-28 | -$119.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.75M 10-Q · filed 2022-05-04 | -$295.00K derived: sum of 2 quarters · filed 2023-02-28 | -$124.87M derived: sum of 3 quarters · filed 2023-02-28 | -$124.87M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$126.61M derived: sum of 2 quarters · filed 2023-02-28 | -$126.61M derived: sum of 3 quarters · filed 2023-02-28 | -$126.61M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$124.57M 10-Q · filed 2020-10-30 | -$124.57M derived: sum of 2 quarters · filed 2021-08-03 | -$124.57M 10-Q · filed 2021-11-03 | -$124.57M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | -$1.83M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-30 | -$1.83M 10-Q · filed 2020-10-30 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |